Entering text into the input field will update the search result below

Acadia: Powerful Unfolding Catalysts

Aug. 03, 2022 6:08 AM ETACADIA Pharmaceuticals Inc. (ACAD)6 Comments
BioSci Capital Partners profile picture
BioSci Capital Partners


  • Aside from being launched for Parkinson's, Nuplazid is potentially gaining two additional label expansions.
  • Trofinetide is also poised to gain FDA approval to treat the rare condition, Rett syndrome as early as 1Q 2023.
  • Next year, Acadia is set to report the ADVANCE trial data for schizophrenia.
  • Looking for higher risk/reward options trading ideas? I offer this and much more at my exclusive investing ideas service, Integrated BioSci Investing. Learn More »

3d illustration of brain white matter of cerebral hemisphere anatomy.


If you aren't willing to own a stock for 10 years don't even think about owning it for 10 minutes. - Warren Buffett

In biotech investing, a regulatory binary event is crucial to your investment thesis. As such, it's important that

Thanks for reading! To read the full article, CLICK HERE. To get the latest articles, please hit the orange “Follow” button on top.

Be sure to check out our private investment research community, Integrated BioSci Investing.

Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.

Very professional, extremely knowledgeable and very honest … I would highly recommend this service and his stock picks have been very profitable.

Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.

Click here for a FREE TRIAL.

This article was written by

BioSci Capital Partners profile picture
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.  Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains. Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook. In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, I'm not giving you professional medical advice. Before embarking on any health-changing behavior, make sure you consult with your own doctor.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

The Board needs to sell this dog and put shareholders out of their misery.
" I viewed the 126.3% R&D increase positively because the capital invested today can turn into blockbuster profits tomorrow."

It was just a one-timer of $60m (upfront payment).

"... A third of the committee members voted for approval..."

12 members, 3 votes for approval...too complicate to calculate for me, but it smells like a fourth.
Vikdan profile picture
Being traded up today before the FDA rejection. Will plummet back to $12 +/-
@BioSci Capital Partners Thank you and appreciate your balanced analysis. It may take more time but ACAD will become a successful Pharma company. As you can see, the world has many naysayers though.
Vitamanrocks1 profile picture
....and no, they don't have anything for Tourette syndrome as you state in your article. Please review your work.
Vitamanrocks1 profile picture
Short the glaring incompetence exhibited by Serge and Steve on any and every spike and you'll do fine.
Due to such a long period with zero successes and ongoing offerings (the next one will be this or next quarter) it actually appears the BOD may actually be shorting their own stock, no doubt from an offshore account.
Acadia will continue to go nowhere.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.